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Analyzing the flow of biological information is a fundamental challenge for basic sciences. The emerging results will
then lend themselves to the development of new approaches for medical applications. Toward this end, the
products of protein/lipid glycosylation deserve special attention. The covalent attachment of sugars to these carriers
means much more than just a change of the carriers’ physicochemical properties. In principle, the ubiquitous
presence of glycoconjugates and the close inspection of the particular structural ‘talents’ of carbohydrates provide
suggestive evidence for information coding by sugars. In fact, the theoretical number of ‘words’ (oligomers) formed
by ‘letters’ (monosaccharides) is by far higher than by using nucleotides or amino acids. In other words, glycans
harbor an unsurpassed coding capacity. The cyto- and histochemical detection of dynamic changes in the profile
of cellular glycans (glycome, the equivalent of the proteome) by sugar receptors such as antibodies used as tools
underscores the suitability of carbohydrates for such a task. The resulting staining patterns can be likened to a
molecular fingerprint. By acting as ligand (counterreceptor) for endogenous receptors (tissue lectins), glycan
epitopes become partners in a specific recognition pair, and the sugar-encoded information can then be translated
into effects, e.g. in growth regulation. Of note, expression of both sides of such a pair, i.e. lectin and cognate glycan,
can physiologically be orchestrated for optimal efficiency. Indeed, examples how to prevent autoimmune diseases
by regulatory T cells and restrict carcinoma growth by a tumor suppressor attest occurrence of co-regulation. In
consequence, these glycans have potential to establish a new class of functional biomarkers, and mapping presence
of their receptors is warranted. In this review, the cyto- and histochemical methods, which contribute to explore
information storage and transfer within the sugar code, are described. This introduction to the toolbox is flanked
by illustrating the application of each type of tool in histopathology, with focus on adhesion/growth-regulating
galectins. Together with an introduction to fundamental principles of the sugar code, the review is designed to
guide into this field and to inspire respective research efforts.
Virtual slides: The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1670639891114983.
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Basic biochemistry teaches that the flow of biological infor-
mation starts with transcription of genes, which code for
proteins or RNA-based regulators of protein production.
Both nucleotides and amino acids are linked to oligo- and
polymers by the assembly-line production of linear chains.
As shown in Figure 1a, b, this means that the only para-
meter varied in a respective biopolymer is the sequence of* Correspondence: gabius@tiph.vetmed.uni-muenchen.de
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article, unless otherwise stated.the building blocks. In consequence, the range of sequence
permutations defines the coding capacity of these biomole-
cules. For a trimer, the natural set of four nucleotides will
result in 64 (43) isomers, the alphabet of 20 amino acids in
8000 (203) tripeptides. For coding biological information in
a minimum of space (such constraints become a major
issue on cell surfaces, due to the requirement to present a
wide array of signals), the coding capacity (number of dis-
tinct ‘words’ generated by the ‘letters’ of the respective al-
phabet) needs to reach far higher values. In molecular
terms, one way toward this aim is to generate structural di-
versity beyond the sequence. How can this be accomplishedentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Illustration of the linkage points for oligomer formation in biomolecules by arrows. The phosphodiester bond in nucleic acid
biosynthesis (a) and the peptide bond in protein biosynthesis (b) yield linear oligomers. In contrast, the glycosidic linkage in oligosaccharides
can involve any hydroxyl group, opening the way to linear and also branched structures (c). Using D-glucose (Glc) as an example, its active form
UDP-Glc allows conjugation of this sugar to carbohydrate acceptors to any hydroxyl group, as symbolized by arrows directed towards the hydroxy
groups (for list of resulting diglucosides, please see Table 1). The anomeric position in chain elongation can vary, as symbolized by two bold arrows
pointing away from the molecule (from [1], with permission).
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of nucleic acids and proteins? Which type of biomolecule
can meet this demand and also has the suited wide distri-
bution in Nature? These questions will be answered in the
next section by turning to biomolecules well-known for
their capacity to store energy, i.e. the carbohydrates.
Carbohydrates: the third alphabet of life
A brief inspection of the structure of the most common
sugar is enormously illuminating: D-Glucose (Glc) intro-
duces the reader to i) the presentation of chemically rather
equal hydroxyl groups for versatile formation of glycosidic
linkages and ii) the principle of anomery, a type of isomery
concerning the constellation at the anomeric center (the
C1 atom) after ring formation (for details, please see
Figure 2). As consequence, each hydroxyl group can be en-
gaged as acceptor. Activation of a sugar at the anomeric
center (here UDP-Glc) generates the donor, present in two
anomeric constellations (α or β). The site-specific coupling
reaction is driven by a glycosyltransferase (for an illustration
with D-Glc as example, please see Figure 1c) [1]. A result-
ing diglucoside therefore is not simply characterized as
Glc-Glc as is the case for a dipeptide. Information on the
anomeric character (α or β) and the two connection points
(theoretically possible are 1,1; 1,2; 1,3; 1,4; 1,6) is necessary
for describing the individual disaccharide (to give an ex-
ample, maltose is Glcα1,4Glc; for a listing of all naturally
occurring diglucosides, please see Table 1).Figure 2 Illustration of the equilibrium including the two anomeric fo
hexopyranose and the open-chain forms in equilibrium are given in the boIn addition, as further sources of variability, the ring size
(furanose or pyranose) can differ, branching of chains is
possible and, like in proteins, substitutions (e.g. phosphor-
ylation) can be introduced. Assuming an alphabet size of
20 for model calculations, the sugars (the third alphabet of
life) can theoretically build 11.264×106 trimers, compared
to 64/8000 for the first (nucleotides) or second (amino
acids) alphabets [2]. Even though the donor-acceptor bio-
chemistry restricts the panel size, the comparison given in
Figure 1 graphically documents the second-to-none cap-
acity of carbohydrates for coding. Nonetheless, compared
to the set of nucleotides and amino acids, less is com-
monly taught in biochemistry courses about the elements
of the sugar alphabet.
In Nature, the sugar alphabet starts with Glc (building
block of starch and cellulose, which differ in anomeric
linkage type of the 1,4-connected units, highlighting the
importance of seemingly small structural changes) and its
2’-derivative N-acetyl-glucosamine (GlcNAc, unit of chi-
tin) (Figure 3). These biomacromolecules actually are the
most abundant polymers on earth (please see below). Epi-
mers of Glc (a switch of a hydroxyl group from the ener-
getically preferred equatorial to the axial position; please
see the 4’-epimer galactose (Gal) and the 2’-epimer man-
nose (Man) in Figure 3), deoxy sugars, uronic acids and
other anionic carbohydrates further belong to the sugar
alphabet (Figure 3). Linking the ‘letters’ to ‘words’ will
proceed without a genetic blueprint. Instead, factors suchrms of D-glucose. The percentages of presence of the two anomeric
ttom line (from [1], with permission).
Table 1 Naturally occurring disaccharides formed from
two glucose units










All disaccharides are conversion or degradation products of natural polysaccharides
and glycosides, except for trehalose which is present in bacteria, fungi and insects;
arrows depict involvement of anomeric centers (from [1], with permission).
Figure 3 Illustration of the alphabet of the sugar language. Structural
acceptor positions (arrows) in glycoconjugates are given for each letter. Fo
(6-deoxy-L-mannose) and arabinose are introduced during chain elongation,
of glucuronic acid at C-5. The 1C4 conformation of IdoA (a) is in equilibrium w
can be 2-sulfated (please see Figure 7d). All other “letters” are D-sugars. Ne
chains in animal glycoconjugates. Kdo is a constituent of lipopolysacchari
cell wall polysaccharides of green algae and higher plants. Foreign to mam
furanose ring form of D-galactose and also D/L-arabinose indicated by an ital
for the pentose arabinose, e. g. in mycobacterial cell wall arabinogalactan and
arabinogalactan and the β1,3/6 linkage in lipopolysaccharides (from [1], with
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overall coding capacity in oligosaccharides is further en-
hanced, as for proteins, by introducing substitutions such
as phosphorylation and sulfation (for physiologically prom-
inent examples, please see Figure 4). In aggregate, the sugar
alphabet, by virtue of the distinct chemical properties of
sugars, enables enormous structural variability beyond the
sequence: anomeric status, linkage formation involving
different acceptor sites and ring size, with frequent occur-
rence of branching and site-specific presence of modifica-
tions, make this possible. Thus, the coding capacity of the
sugar language is orders of magnitude higher than for nu-
cleic acids and proteins.
Carbohydrate oligomers (glycans) or polymers (polysac-
charides) are ubiquitous. Cellulose and chitin are the two
most abundant organic compounds (with estimations forrepresentation, name and symbol as well as the set of known
ur sugars have L-configuration: fucose (6-deoxy-L-galactose), rhamnose
whereas L-iduronic acid (IdoA) results from post-synthetic epimerization
ith the 2SO form (b) in glycosaminoglycan chains where this uronic acid
u5Ac, one of the more than 50 sialic acids, often terminates sugar
des in the cell walls of Gram-negative bacteria and is also found in
malian glycobiochemistry, microbial polysaccharides contain the
ic “f” derived from the heterocyclus furan. The α-anomer is prevalent
lipoarabinomannan. β1,5/6-Linked galactofuranoside is present in the
permission).
Figure 4 Illustration of phosphorylated (phosphated) and sulfated (sulfurylated) glycan “words”. 6-Phosphorylation of a mannose
moiety (in the context of a mannose-rich pentasaccharide) is the key section of a routing signal in lysosomal enzymes (a), 4-sulfation of the
GalNAcβ1,4GlcNAc (LacdiNAc) epitope forms the “postal code” for clearance from circulation by hepatic endothelial cells of pituitary glycoprotein
hormones labeled in such a way (b), the HNK-1 (human natural killer-1) epitope (3-sulfated GlcAβ1,3Galβ1,4GlcNAc) is involved in cell adhesion/
migration in the nervous system (c) and the encircled 3-O-sulfation in the pentasaccharide’s center is essential for heparin’s anti-coagulant activity
(d). All sugars are in their pyranose form. Please note that the central glucosamine unit has N,O-trisulfation and that the 2-sulfated IdoA, given
in the 1C4 conformation, can also adopt the hinge-like
2SO skew-boat structure (please see Figure 3; about 60% or more for the
2SO form in
equilibrium depending on the structural context) when present within glycosaminoglycan chains of the proteoglycan heparin. 2-Sulfation of IdoA
serves two purposes: favoring the hinge-like 2SO conformation and precluding re-conversion to GlcA (from [1], with permission).
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[3]. On eukaryotic cell surfaces, the glycan part of glyco-
conjugates (hybrid molecules of sugar and lipid/protein,
termed glycoproteins/proteoglycan or glycolipid [4-8] is
prominently positioned and readily accessible. The forma-
tion of at least 41 bonds between sugar and protein, with
eight amino acids and 13 sugars involved, highlights the
wide diversity of these types of conjugation in Nature [9].
Necessarily, an intricate enzymatic machinery for glycan
assembly and remodeling (by glycosyltransferases, glycosi-
dases and substitution-introducing enzymes such as sulfo-
transferases [4-8,10]) has developed to realize the actually
presented set of glycans on cells (glycome) from the panel
of theoretically possible glycans. In human cells, proteins
destined for cell surface residence or secretion commonly
carry glycan chains at the asparagine: Asn of the glycosyla-
tion sequon (Asn-X-Ser/Thr; X≠Pro), the amide’s nitrogen
(N) acting as acceptor (thus the term N-glycosylation).
But this high-level complexity in structure comes at a
scientific price: “in this remarkable age of genomics,
proteomics, and functional proteomics, I am often
asked by my colleagues why glycobiology has apparently
lagged so far behind the other fields. The simple answeris that glycoconjugates are much more complex, varie-
gated, and difficult to study than proteins or nucleic
acids” [11]. To address this problem and set the stage
for full-scale glycome analysis led to development of so-
phisticated analytical procedures, even separating and
identifying structural isomers reliably [12]. Their avail-
ability opens the door to comparative studies of glycan
sequences in clinical specimens in the quest to define
glycobiomarkers for diseases such as cancer, CA19-9 be-
ing an example [13-15].
In cyto- and histochemistry, the methods to detect gly-
can presence gained in specificity over time. Initially,
carbohydrates were visualized by applying protocols like
the PAS procedure (based on oxidizing vicinal hydroxyl
groups of carbohydrates to reactive aldehydes) or stains
such as Alcian blue (for glycosaminoglycans). These
methods were replaced with marked increase in speci-
ficity by applying sugar receptors [16-21]. Known from
transfusion medicine, certain antibodies are reactive
with carbohydrate epitopes such as the blood group
ABH determinants [22], and the monoclonal-antibody
technology accounts for access to custom-made tools. The
second class of sugar receptors used as laboratory tools
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They are referred to this way due to their capability to
aggregate erythrocytes (haemagglutination) in a sugar-
dependent manner [23,24]. These receptor proteins, sepa-
rated from the class of antibodies and from enzymes,
which process the bound sugar, are called lectins (for an
overview on the history of lectinology starting with detec-
tion in snake venom and plant extracts, please see [25]).
The large number of lectins from plants and invertebrates
makes detailed monitoring of distinct glycome aspects
possible, e.g. on status and type of sialylation or substitu-
tion of the core of N-glycans [16-21]. Especially these fea-
tures are susceptible to changes upon altering genetic or
microenvironmental parameters [26-28]. Sialylation can
physiologically mask a glycan chain, the addition of the
bisecting GlcNAc residue (a molecular ‘wedge’ between
two glycan branches) or a fucose moiety to the N-glycan
core is not a merely subtle structural difference. Instead, it
is a molecular switch for the glycan’s conformational dy-
namics, with important functional consequences during
and after glycoprotein maturation [29-34]. What this
popular method of specific detection of glycan epitopes
also teaches is that these structures can serve as ligands
(counterreceptors) in molecular recognition. Glycan de-
tection by lectins (as tools) thus prompts the question on
the presence of endogenous receptors, to read the
sugar-encoded information and translate it into cellular
responses.
Lectins: translators of the sugar code
The wide diversity of glycan structures in Nature let us
expect an equally broad set of lectins. The diversity
should concern both the number of families, defined by
the folding pattern, and the number of members in each
family. On the level of protein folds with capacity to
bind sugars, this expectation is borne out: at least 14
types have developed in phylogenesis to endow animal/
human proteins with lectin activity (Table 2). Once
established, each domain has undergone evolutionary di-
versification to generate a lectin family. This holds true
for all cases listed in Table 2. Tracing the routes to di-
versity in individual families, e.g. C-type lectins and
galectins, gives an impression on the ways sequences in
the carbohydrate recognition domains (CRD) and their
spatial modes of presentation can diverge including oc-
currence of single nucleotide polymorphisms in lectin
genes [35-39]. Formation of non-covalent aggregates or
the tandem-repeat display underlie the lectins’ cross-
linking capacity, depending on the presence of matching
glycans. In this respect, the binding of lectins to their
cellular targets markedly benefits from a special property
of glycans: acquisition of only few energetically preferred
conformers by limited flexibility [40,41]. In contrast,
peptides will adopt certain conformations only whenembedded into the context of a protein, otherwise be
highly flexible. In other words, glycans often acquire
key-like conformations. They are suited to be accommo-
dated into a complementary binding site (CRD; molecu-
lar lock). This favorable factor for the thermodynamics
of binding adds to the advantageous features of glycans
in information coding outlined above.
Turning back to the protein side, genes for CRDs are
widely disseminated in the genome. As integral part of
many proteins, these domains can even be linked to
other functional sites. This design leads to multifunc-
tional proteins, e.g. collagen-like tails for aggregation in
innate immunity lectins or cell- and carbohydrate-
binding sites in a slime mold lectin working together to
effect ordered cell migration [43-45]. Evidently, homing
in on distinct targets on bacterial surfaces or executing a
certain task in guiding cells can take more than being
able to bind a certain sugar. Intriguingly, lectin reactivity
of glycoconjugates in their physiological context can be
markedly modulated. In total, structural and topological
factors of glycans on six levels cooperate to let lectins
find their natural counterreceptors [41]. The attained
specificity in target recognition lays the foundation for
the spectrum of lectin functions compiled in Table 3.
Exemplarily looking at routing/delivery processes, cargo
selection and transport via lectins, e.g. of enzymes with
the mannose-6-phosphate signal (Figure 4a) to lyso-
somes, glycoproteins with multiantennary N-glycans to
the apical side of polarized cells and of a cell adhesion
molecule (L1) to axonal membranes [46-49], illustrate the
reason why glycans are likened to a postal code. Orches-
tration of glycan/lectin expression goes far beyond trans-
port processes.
In tumor biology, a deficiency in suppressor activity
can cause the release from growth control. The study
of reconstitution of activity of the tumor suppressor
p16INK4a in vitro in pancreas carcinoma cells (Capan-1)
has revealed the co-regulation of glycogenes (encoding
several glycosyltransferases and two enzymes in sialic
acid biosynthesis, a sugar at terminal positions regulat-
ing recognition [50]) with two distinct lectins (transcrip-
tionally and post-transcriptionally) in order to make
cells susceptible for lectin-dependent anoikis induction
[51-53]. In detail, decreased synthesis of sialic acid re-
duces α2,6-sialylation on the cell surface, this in turn fa-
voring binding and cross-linking of the fibronectin
receptor (α5β1-integrin) by galectin-1 and the ensuing
activation of caspase-8 [51,53]. Expression of the physio-
logical antagonist (galectin-3) is decreased for optimal
cellular responsiveness to galectin-1. This homodimeric
galectin is also the trigger element for growth regulation
in other cases, with a different counterreceptor. Instead
of a glycoprotein, binding of ganglioside GM1 in neuro-
blastoma cells and activated effector T cells, in both
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into the active counterreceptor by a sialidase [54-58],
starts the regulatory cascade. The second sialic acid moi-
ety of ganglioside GD1a (please see Figure 3 for struc-
ture of sialic acid) at its hexasaccharide terminus thus
impairs the reactivity of the entire sugar chain of the
ganglioside to preclude lectin recognition, its removal fa-
cilitating the binding to galectin-1.
Evidently, dynamic remodeling of glycans on the cell sur-
face is an efficient means to let cells swiftly become respon-
sive to distinct lectins, without the need for a completeTable 2 Overview of folds with capacity to bind sugars and o
Type of fold Example for lectin
β-sandwich (jelly-roll) a) galectins
b) calnexin, calreticulin
c) ERGIC-53, VIP36, VIPL
d) CRDa of Fbs1 in SCF E3 ubiquitin
glycanase
e) pentraxins
f) G-domains of the LNS family (lami
C-type asialoglycoprotein receptor, collectin
I-type (Ig fold) N-CAM, TIM-3, siglecs
P-type mannose-6-phosphate receptors (MR
MR homology domain (erlectin, OS-9
β-trefoil a) fibroblast growth factors
b) cysteine-rich domain of C-type m
receptor
c) lectin domain in GalNAc-Tsb involv
glycosylation
d) hemolytic lectin CEL-III of sea cuc
EW29 of earthworm
β-propeller a) 4-bladed: tachylectin-3
b) 5-bladed: tachylectin-2
c) 6-bladed: tachylectin-1
β-prism I secretory proteins zg16p/b
β-prism II pufferfish (fugu) lectin
β-barrel with jelly-roll topology tachylectin-4, eel (Anguilla anguilla) a
Fibrinogen-like domain a) ficolins
b) intelectins (mammalian, Xenopus)
c) tachylectin-5
d) slug (Limax flavus) lectin
Link module CD44, TSG-6, LYVE-1, aggregating pro
Hevein-like domain Tachycytin and spider (Selenocosmia
cobra venom cardiotoxin
(β/α)8 barrel (glycoside hydrolase
family 18)
YKL-40 (human cartilage glycoprotein
lectin)
Short consensus repeat (complement
control protein module)
Factor H (complement regulator)
acarbohydrate recognition domain, bN-acetylgalactosaminyltransferases; adapted froneosynthesis. The specificity of counterreceptor recognition
by tissue lectins guarantees correct reading of signals. As
the in vitro examples indicate, lectins are expressed not
only by normal cells but also in malignancy. Purification
from extracts of tumor cells or tissue using affinity
chromatography provides material for characterization
and functional testing [59,60]. Given this expression of
the glycobiological effectors in tumors, a new research
area is opened, with the potential to identify a prognostic
indicator and targets for therapy [61,62]. To test these as-





ligase and peptide-N- Man3GlcNAc2; mannopentaose
glycosaminoglycans, MOβDG, 3-sulfated Gal, Gal-
NAc and GlcA, Man-6-phosphate
nin, agrin) heparin
s, selectins Fuc, Gal, GalNAc, Man, heparin tetrasaccharide
Man6GlcNAc2, HNK-1 epitope, α2,3/6-sialylated
glycans




acrophage mannose GalNAc-4-sulfate in LacdiNAc
ed in mucin-type O- GalNAc








N-acetylated sugars sialic acid
teoglycans hyaluronic acid
huwena) neurotoxin; GalNAc; heparin-derived disaccharide
-39; chitinase-like (GlcNAc)n
glycosaminoglycans, sialic acid
m [42], with permission.
Table 3 Functions of animal and human lectinsa
Activity Example of lectin
Recognition of stem region of N-glycans, a signal for ubiquitin conjugation when accessible in
incorrectly folded glycoproteins
F-box proteins Fbs1 and Fbs2, which comprise the ligand-specific part of SCFb ubiquitin ligase
complexes
Molecular chaperones with dual specificity for Glc2/Glc1Man9GlcNAc2 and protein part of nascent
glycoproteins in the ER
Malectin/ribophorin I complex, calnexin, calreticulin
Targeting of misfolded glycoproteins with Man8-5GlcNAc2 as carbohydrate ligand to ER-associated
degradation (ERAD)
EDEM1,2c/Mnl1 (Htm1) (lectins or glycosidases?), Yos9p (MRHd domain) in yeast, erlectin (XTP3-Be)
and OS-9f in mammals
Intracellular routing of glycoproteins and vesicles and apical delivery Comitin, ERGIC53g and VIP36h (probably also ERGLi and VIPLj), galectins-3, -4 and -9, P-type lectins
Intracellular transport and extracellular assembly Non-integrin 67 kDa elastin/laminin-binding protein
Enamel formation and biomineralization Amelogenin
Inducer of membrane superimposition and zippering (formation of Birbeck granules) Langerin (CD207)
Cell type-specific endocytosis Cysteine-rich domain (β-trefoil) of the dimeric form of mannose receptor for GalNAc-4-SO4-bearing
glycoprotein hormones in hepatic endothelial cells, dendritic cell and macrophage C-type lectins (man-
nose receptor family
members (tandem-repeat type) and single-CRDk lectins such as trimeric langerin/CD207 or tetrameric
DC-SIGNl/CD209), hepatic and macrophage asialoglycoprotein receptors, HAREm, P-type lectins
Recognition of foreign glycans (β1,3-glucans, cell wall peptidoglycan, LOSn and LPSo),
mycobacterial glycolipid or host-like epitopes
CR3p (CD11b/CD18, Mac-1 antigen), C-type lectins such as collectins, DC-SIGN, dectin-1, Mincle and
RegIIIγ (murine)q or HIP/PAP (human), ficolins, galectins, immulectins, intelectins, Limulus coagula-
tion factors C and G, siglecs, tachylectins
Recognition of foreign or aberrant glycosignatures on cells (including endocytosis or initiation of
opsonization or complement activation) and of apoptotic/necrotic cells (glycans or peptide
motifs)
Collectins, C-type macrophage and dendritic cell lectins, CR3 (CD11b/CD18, Mac-1 antigen), α/Θ-
defensins, ficolins, galectins, pentraxins (CRP, limulin), RegIIIγ (HIP/PAP), siglecs, tachylectins
Targeting of enzymatic activity in multimodular proteins Acrosin, Limulus coagulation factor C, laforin, β-trefoil fold ((QxW)3 domain) of GalNAc-Tsr involved
in mucin-type O-glycosylation, frequent in microbial glycosylhydrolases for plant cell wall polysac-
charides, termed carbohydrate-binding modules
Bridging of molecules Cerebellar soluble lectin, cytokines (e.g. IL-2s–IL-2R and CD3 of TCR), galectins
Induction or suppression of effector release (H2O2, cytokines etc.) Chitinase-like YKL-40, galectins, I-type lectins (e.g. CD33 (siglec-3), siglecs-7 and -9), selectins and
other C-type lectins such as CD23, BDCA2 and dectin-1, Toll-like receptor 4
Alteration of enzymatic activities in modular proteins/receptor endocytosis via lattice formation Mannan-binding lectin (acting on meprins); galectins
Cell growth control, induction of apoptosis/anoikis and axonal regeneration Amphoterin and other heparin-binding proteins, cerebellar soluble lectin, chitinase-like lectins, C-
type lectins, galectins, hyaluronic acid-binding proteins, siglecs (e.g. CD22 and CD33)
Cell migration and routing Galectins, hyaluronic acid-binding proteins (CD44, hyalectans/lecticans, RHAMMt), I-type lectins,
selectins and other C-type lectins
Cell–cell interactions Galectins, gliolectin, I-type lectins (e.g. siglecs, N-CAMu, P0 or L1), selectins and other C-type lectins

















Table 3 Functions of animal and human lectinsa (Continued)
Cell–matrix interactions Calreticulin, discoidin I, galectins, heparin- and hyaluronic acid-binding lectins including hyalectans/
lecticans
Matrix network assembly Galectins (e.g. galectin-3/hensin), non-integrin 67 kDa elastin/laminin-binding protein, proteoglycan
core proteins (C-type CRD and G1 domain of hyalectans/lecticans)
aadapted from [42], with permission, and extended.
bSkp-1-Cul1-F-box protein complex.
cER degradation enhancing α-mannosidase-like protein.
dmannose-6-phosphate receptor homology.
eXTP3-transactivated gene B precursor.
fosteosarcoma 9.
gER-Golgi intermediate compartment protein (lectin) (MW: 53 kDa).




ldendritic cell-specific ICAM-3-grabbing nonintegrin.
mhyaluronan receptor for endocytosis.
nlipooligosaccharide.
olipopolysaccharide.
pcomplement receptor type 3.
qmember of regenerating (reg) gene family of secreted proteins.
rUDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases.
sinterleukin-2.
treceptor for hyaluronan-mediated motility.
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work) and the expression of binding partners – in view of
the mentioned cases for orchestration of both sides of this
recognition system – are the central challenges. They are
mastered by strategic combination of chemistry and bio-
chemistry, adapted to cyto- and histochemistry.
How to detect tissue lectins
Having described glycans as information-bearing biomole-
cules and plant/invertebrate lectins as tools to characterize
the cellular glycophenotype and disease-associated alter-
ation (please see first section in Table 4), the principle to
follow for the design of lectin-detecting probes is rather
obvious: use glycans in search of binding sites (CRDs).
Products from chemical synthesis of oligosaccharides (for
an introduction into this field, please see [63]) or from
purification from natural sources such as glycoproteins
can fulfill any request for product specifications. Next,
the issues of turning glycans into high-affintiy binders
and of introducing a label are addressed. As the nat-
ural role model for glycan presentation in clusters
teaches, the conjugation of a carbohydrate derivative
to a scaffold (protein or synthetic polymer) is a sui-
table strategy to achieve the affinity increase. This
synthetic attachment leads to neoglycoproteins/neo-
glycoconjugates (the prefix neo describing the syn-
thetic origin), with the expected enhancement of lectin
reactivity when moving from mono- to polyvalency
[64-67]. Having prepared the conjugate, introducing a
label is the final step of the synthetic scheme. A na-
tural mode of labeling is the association of glycan
presentation with an enzymatic activity, e.g. in alka-
line phosphatase or horseradish peroxidase [68-70].
This principle can be adopted by preparing enzyme-
neoglycoprotein conjugates or neoglycoenzymes [71,72].
Of note, the reactivity of the high-mannose-type N-
glycans of the plant peroxidase, a component of stain-
ing kits, with mannose-specific lectins in situ, e.g. the
C-type tandem-repeat-type receptor on macrophages,
gives reason to perform rigorous controls for specifi-
city to exclude a false-positive outcome in cyto- and
histochemical processing.Table 4 The four classes of reagents used in glycocyto- and h
Experimental aim Type of reagent E




Detect accessible sites binding a distinct
carbohydrate epitope
Neoglycoconjugate D




Detect accessible ligands (glycan/peptide)
for an endogenous lectin
Tissue lectin D
c
From [73], with permission.In general, chemistry facilitates to introduce any label
such as biotin or fluorescent dyes into the scaffold to let
the neoglycoconjugates enter routine practice. This ap-
proach is referred to as glycocyto- and histochemistry
(please see second section in Table 4). Unless receptors
are blocked by their engagement with high-affinity tissue
sites or harmed by processing steps such as fixation, pres-
ence of carbohydrate-binding proteins can then be com-
prehensively studied. Using the same type of scaffold and
label, in combination with stringent controls (testing
carbohydrate-free scaffold and running inhibition assays),
will enable a cell/tissue profiling of capacity to bind carbo-
hydrate epitopes. Histopathologic application of these
tools not only ascertained the validity of the concept but
also indicated the potential to distinguish cell/tumor types
[74-77]. At 95% sensitivity/72% specificity binding of the
pentasaccharide of ganglioside GM1 (mentioned above as
galectin-1 counterreceptor) occurred to mesothelioma
[78], and GalNAc binding was different between sections
of typical and atypical carcinoid tumors of the lung [79].
Using the strategic combination of carbohydrate chemis-
try to synthesize biologically relevant di- and oligosa-
ccharides, e.g. the Thomsen-Friedenreich (T) antigen or
histo-blood group determinants, with glycohistochemistry
answered the question positively for tissue presence of
respective receptors, e.g. in breast and lung cancer
[80,81]. Based on analysis of 187 lung cancer cases a
favorable prognostic correlation was discerned for
binding of the histo-blood group A and H (but not
B) trisaccharides [81]. In this respect, members of the
family of galectins (galactoside-binding β-sandwich-
fold proteins with a sequence signature prominently
harboring a Trp moiety responsible for contact to the
Gal-moiety of cognate glycans [38]) are candidate re-
ceptors, owing to their involvement in growth processes
and the known reactivity to these epitopes [82,83].
Thus, results from glycocyto- and histochemistry give
direction for the next step to take in analyzing the
glycan-based communication, i.e. to purify the tissue
lectins and work with lectin-specific antibodies (please
see third section in Table 4), here illustrated exemplarily
for galectins as example.istochemical analysis
xample
onitoring the presence of β1,6-branching in N-glycans or of sialylated
ewis epitopes
etecting binding sites for sialylated Lewis epitopes in colon cancer
erforming immunohistochemical galectin fingerprinting in colon cancer
with prognostic relevance for galectins)
elineating prognostic relevance for galectin-3 binding in head and neck
ancer sections
Gabius and Kayser Diagnostic Pathology 2014, 9:4 Page 10 of 14
http://www.diagnosticpathology.org/content/9/1/4The galectin network in tumors
Following the directives given above, sugar-specific staining
guides selection of the resin-bound ligand for affinity chro-
matographic purification of proteins(s) with respective spe-
cificity. Glycohistochemical monitoring is thus more than a
screening. The strong staining intensity specific for β-
galactosides (of neoglycoproteins bearing lactose or glyco-
proteins after sialic acid removal from the glycan chains) in
muscle biopsy specimens (itself of diagnostic value in fiber
typing on fixed material [84]) prompted lectin purification
using a resin presenting lactose and raising lectin-specific
antibodies with the protein now termed galectin-1. The en-
suing immunohistochemical work revealed the expectable
similarity between the glyco- and immunohistochemical
staining patterns [84]. The Ca2+-independent tissue reactiv-
ity to lactose moieties or the N-acetyllactosamine terminus
of N-glycan chains of asialofetuin is thus attributable to
galectin-1, the most prevalent member of this lectin family
in muscle (mentioned above as potent growth regulator),
and galectins are also found in tumors. Reflecting the ap-
parent diversification of the ancestral gene in this lectin
family [35,38], more than one galectin can be expressed
in tumors, initially documented by histopathology using
non-crossreactive antibodies in breast cancer [85]. Of
course, the localization profiles can differ, and parame-
ters such as degree of differentiation can affect the re-
sults to non-identical extents for the proteins tested.
Consequently, galectin fingerprinting with non-crossreactive
antibodies, and not a focus on a single family member, is
advisable to get a clear view on effector presence.
Respective studies on colon and on head and neck cancer
as well as bladder carcinoma went beyond underscoring
the network concept by disclosing prognostic relevance for
distinct family members, e.g. galectins-1 and -4 in colon
cancer [86,87], galectin-7 in hypopharyngeal cancer
[88,89] as well as galectins-2 and -8 in urothelial car-
cinoma [90]. Moreover, differential diagnosis and cell-
lineage characterization are aided by this fingerprinting
[91,92]. Combined with syntactic structure analysis, which
assesses cell distribution relative to staining parameters for
tumor/inflammatory cells including measuring structural
entropy (for methodological details, please see [93,94]), fur-
ther prognostic indicators can be delineated. Distances
between tumor cells (positivity for galectin-8 at high inten-
sity) and lymphocytes as well as between galectin-1-positive
tumor cells were of prognostic relevance in testicular can-
cer patients with lung metastases [95]. To avoid false-
negative results in such studies, special attention should be
given to the possibility for in situ processing of a galectin
and the appropriate selection of the antibody: proteolytic
truncation by matrix metalloproteinases -2 and -9 of
galectin-3’s N-terminal tail can remove the antigenic
epitope from the lectin and hereby be the reason for
making the lectin invisible.Two lines of experimental evidence guide from this fin-
gerprinting to the next methodological step: i) the glyco-
phenotype analysis with plant lectins and ii) the functional
correlation between receptor (lectin)/counterreceptor (gly-
can) expression, as outlined above, both encourage to test
tissue lectins as tools. After having paved the way to these
proteins in sufficient quantities by recombinant expression,
galectin cyto- and histochemistry could be realized (please
see fourth section in Table 4). As plant agglutinins, human
lectins can readily be labeled, under activity-preserving con-
ditions, and then employed to trace reactive sites in cells, in
different types of specimens [96-101]. In tumor pathology,
galectins-3 binding proved of prognostic relevance in colon
and advanced laryngeal/hypopharyngeal cancer [102,103].
Interestingly, a modification of the lectin, e.g. by altering
structural parameters relevant for stability or clearance
[104,105], is not neutral but can change binding properties
or harm activity. Combining the monitoring of distinct
characteristics of the glycophenotype such as the status of
α2,6-sialylation with measuring presence of galectins
and their reactivity, as performed for colon cancer
[28,86,87,103], along with monitoring of functionally
relevant gene products such as the fibronectin receptor
(α5β1-integrin), a galectin counterreceptor in carcinoma
growth regulation via cell cycle arrest or anoikis induc-
tion [51,106,107], has potential to take mapping of epi-
tope presence to function-oriented analysis. Similarly,
galectin expression along with its apoptosis-inducing
counterreceptor CD7 explains the clonal selection to-
ward CD4+CD7- T leukemic cells during progression of
the Sézary syndrome [108]. The presented principles
underlying the glyco- and galectin cyto- and histochem-
ical approaches are not only instrumental for the glyco-
biological aspect of specimen characterization. They
also have relevance beyond studying glycobiological ef-
fector pathways. Examples inspiring further applications
will be given in the next section.
Carrier-immobilized/free ligands tracing their receptors
The localization of galectins by labeled (neo)glycoconju-
gates documents maintained capacity for specific binding
even after fixation of the specimen and its exposure to or-
ganic solvents. If this prerequisite is fulfilled for a receptor,
more types of natural ligands can serve the purpose to
track down presence of accessible binding sites. In the first
step, a conjugation to a labeled scaffold without impairing
the ligand activity is performed. Using estradiol and testos-
terone, attached to albumin as inert carrier, presence of
steroid hormone receptors was detected in tissue sections
of lung cancer and in pleural effusion of mesothelioma,
here with relation to the S-phase-related tumor cell frac-
tion [109,110]. When similarly presented by a carrier,
anthracylin reactivity was revealed in sections of small cell
lung cancer sections, with prognostic relevance [111]. In
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tion, positivity also is an incentive for biochemical work to
determine the nature of binding sites for the scaffold-
presented ligands, the case study on galectin isolation from
muscle mentioned above.
Mimicking the (ga)lectin histochemical approach of
glycan profiling, any protein is suited for localization of
binding partners, if labeling does not harm the inter-
action with counterreceptor(s). To achieve localization
biotinylation by signal generation has been found applic-
able for interleukin-2 [112,113], erythropoietin [114], the
epidermal growth factor [115,116], macrophage migration
inhibitory factor, with prognostic relevance in carcinoid tu-
mors of the lung [79], and sarcolectin interacting with this
broad-spectrum pro-inflammatory cytokine [81,117,118]. In
order to select the least activity-reducing type of modifica-
tion for labeling, systematic study of the influence of amino
acid modification with group-specific reagents on the inter-
action is advised. In principle, this approach extends the
scope of immunohistochemical localization, especially in
cases when a ligand can bind to several distinct receptors
or when characterizing the range of interaction partners
has not yet been taken to the biochemical level.
Conclusions
Carbohydrates can form oligo- and polymers, with equally
wide distribution as that of nucleic acids and proteins. Bio-
chemically, they are more than fuel or concrete for cell
walls. The consideration of the chemical properties of
sugars explains their amazing capacity to turn the ‘letters’
of this alphabet (monosaccharides) into an unsurpassably
large array of ‘words’. While being central to the enormous
versatility of sugar-based coding, this structural complexity
poses an extraordinary challenge for compound analysis,
much greater than for any other class of biopolymer. Fit-
tingly, respective methods have become available only re-
cently. Physiologically, the molecular meaning of cellular
glycan determinants can be translated into responses by re-
ceptors (lectins). Evidently, the glycophenotype of cells has
a functional dimension, nourishing the expectations for
biomedical relevance of its characterization.
Based on the concept of the sugar code outlined above
four technical approaches enable histopathologists to de-
fine respective aspects cyto-and histochemically:
1. Glycan profiling by carbohydrate-specific antibodies
or plant/invertebrate lectins
2. Profiling of carbohydrate-binding sites by (neo)
glycoconjugates
3. Immunohistochemical detection of lectins and
fingerprinting for family members in an emerging
network
4. Profiling cognate sites by endogenous lectins
(in combination with 3. enabling colocalization)Taking this step-by-step approach is currently reveal-
ing correlations between clinical and glycopathological
parameters, encouraging further efforts. Work in vitro
substantiates the assumed effector functionality of lec-
tins by targeting distinct counterreceptors such as an
integrin, an adhesion molecule or a ganglioside. These
findings in turn inspire further investigations on clinical
specimens. For monitoring serum samples, the lectin-
reactive clycans of the cellular clycoconjugate(s) then
can become functional glycobiomarkers. Of note, the
approach with carrier-immobilized ligands and labeled
receptor proteins (here lectins) can find application for
epitope-specific localization studies beyond glycopathology.
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